Evaluation of cholesterol levels in hematological malignancies

Aim: The studies show that dyslipidemia may pose a risk factor for the emergence of malignancies. The study evaluates the lipid parameters of patients diagnosed with hematologic malignancy during diagnosis, investigating their relationship with hematologic malignancy and the parameters' effects on remission and its duration. Material and Method: The study included 68 male and 63 female patients with a mean age of 66.1±13.9 years. HDL, LDL, TG, and their TC levels diagnosed with hematologic malignancies due to peripheral smear, bone marrow, and lymph node biopsy between 2015 and 2021 were retrospectively analyzed. According to the statistically analyzed association data between cholesterol levels and hematologic malignancies, p<0.05 was considered significant. Results: Out of all the individuals studied, 12.9% were diagnosed with acute leukemia, 25.1% had chronic leukemia, 32% were diagnosed with multiple myeloma, and 29.7% had lymphoma. Among the patients, 40.5% were in remission, while 59.5% were in relapse clinics. Patients in remission had significantly lower HDL levels compared to those in relapse. However, there was no significant difference between the two groups for LDL, triglycerides, and TC levels. Conclusion: Some studies show that low HDL levels increase the risk of developing hematologic malignancy, low HDL levels decrease survival in patients with hematologic malignancy, and high HDL levels decrease the risk of recurrence development. Although no correlation was found between hematologic malignancy diagnosis groups and lipid levels, this study shows that HDL levels were higher in relapse clinic patients than in the remission group.